TRADING UPDATES: Nexteq confident of meeting full-year expectations
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read moreMon, 10th May 2021 13:49
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read more(Alliance News) - Polarean Imaging PLC shares dropped on Thursday, after the company said it would need to find an additional USD10 million to finance its medium-term ambitions.
Read morePolarean Imaging PLC - London-based developer of medical imaging devices providing magnetic resonance imaging of the lungs - Strategic partner NUKEM Isotopes GmbH buys 9.5 million Polarean shares from Amati Global Investors Ltd, raising its stake to 10.5% from 6.1%. Alzenau, Germany-based NUKEM is a trading company in stable isotopes and noble gases. Amati retains a 4.6% stake in Polarean, down from its last reported level of 9.8%. The shares purchased by NUKEM are worth GBP725,800 at Polarean's current market price.
Read more(Sharecast News) - Lung-focussed MRI technology developer Polarean Imaging said in an update on Thursday that it has received its first de novo order for a new Xenoview polariser.
Read morePolarean Imaging PLC - London-based medical imaging technology developer - Receives its first de novo order for a new Xenoview polariser from an unnamed "top-tier" academic medical centre located in the northeast of the US. Polarean says it continues to have positive meetings and is in active negotiations with additional academic medical centres. Xenoview is a hyperpolarised contrast agent for use with magnetic imaging for the evaluation of lung ventilation in adults and paediatric patients aged 12 years and older. It was approved for use in the US last year.
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.
Read more(Sharecast News) - Advanced MRI technology specialist Polarean Imaging announced a strategic partnership with a clinical imaging intelligence company VIDA Diagnostics on Friday.
Read more(Alliance News) - Polarean Imaging PLC on Friday said that it has partnered with Vida Diagnostics Inc to work on advanced magnetic resonance imaging solutions for the lungs.
Read more(Alliance News) - (Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.
Read morePolarean Imaging PLC - London-based medical imaging technology developer - Announces that following statement on August 29, the reimbursement code for the Polarean Xenoview technology has been assigned to a new technology ambulatory payment classification code which corresponds to a payment range of between USD1,201 to USD1,300 as part of the 2023 medicare hospital outpatient prospective payment system final rule. Notes the codes enables healthcare providers a path to bill for "magnetic resonance imaging with inhaled hyperpolarised xenon-129 contrast agent, chest, including preparation and administration of agent."
Read moreFriday 1 September | |
Diversified Energy Co PLC | Half Year Results |
Monday 4 September | |
Ashtead Technology Holdings PLC | Half Year Results |
Belvoir Group PLC | Half Year Results |
Tuesday 5 September | |
Alumasc Group PLC | Full Year Results |
Ashtead Group PLC | Q1 Results |
Blackbird PLC | Half Year Results |
Craneware PLC | Full Year Results |
DS Smith PLC | Trading Statement |
Ecora Resources PLC | Half Year Results |
Eurocell PLC | Half Year Results |
Gamma Communications PLC | Half Year Results |
GetBusy PLC | Half Year Results |
Headlam Group PLC | Half Year Results |
Johnson Service Group PLC | Half Year Results |
Luceco PLC | Half Year Results |
Michelmersh Brick Holdings PLC | Half Year Results |
Midwich Group PLC | Half Year Results |
Pebble Group PLC | Half Year Results |
Shearwater Group PLC | Full Year Results |
SigmaRoc PLC | Half Year Results |
STV Group PLC | Half Year Results |
Tissue Regenix Group PLC | Half Year Results |
Wednesday 6 September | |
Apax Global Alpha Ltd | Half Year Results |
Ashmore Group PLC | Full Year Results |
Bakkavor Group PLC | Half Year Results |
Barratt Developments PLC | Full Year Results |
Darktrace PLC | Full Year Results |
Halfords Group PLC | Trading Statement |
Hochschild Mining PLC | Half Year Results |
M Winkworth PLC | Half Year Results |
Malin Corp PLC | Half Year Results |
Nexteq PLC | Half Year Results |
Oxford Nanopore Technologies PLC | Half Year Results |
Restaurant Group PLC | Half Year Results |
WH Smith PLC | Trading Statement |
Thursday 7 September | |
Angle PLC | Half Year Results |
Beazley PLC | Half Year Results |
Cairn Homes PLC | Half Year Results |
Currys PLC | Trading Statement |
Direct Line Insurance Group PLC | Half Year Results |
Energean PLC | Half Year Results |
Funding Circle Holdings PLC | Half Year Results |
Genus PLC | Full Year Results |
Hilton Food Group PLC | Half Year Results |
Inspecs Group PLC | Half Year Results |
International Public Partnerships Ltd | Half Year Results |
Lords Group Trading PLC | Half Year Results |
Melrose Industries PLC | Half Year Results |
Mpac Group PLC | Half Year Results |
Playtech PLC | Half Year Results |
Polarean Imaging PLC | Half Year Results |
Safestore Holdings PLC | Trading Statement |
Synthomer PLC | Half Year Results |
Vistry Group PLC | Half Year Results |
WAG Payment Solutions PLC | Half Year Results |
Copyright 2023 Alliance News Ltd. All Rights Reserved. |
(Sharecast News) - Medical device developer Polarean Imaging announced on Tuesday that its Xenoview technology has been granted a new reimbursement code by the US Centers for Medicare and Medicaid Services (CMS).
Read morePolarean Imaging PLC - London-based medical imaging technology developer - Says the US Centers for Medicare & Medicaid Services has established a new reimbursement code for Polarean's Xenoview or 'xenon XE 129' magnetic resonance imaging technology. Code "enables healthcare providers a path to bill for 'magnetic resonance imaging with [the] inhaled hyperpolarised xenon-129 contrast agent...including preparation and administration of agent'." Polarean expects to be informed of the new code's payment level "in the coming weeks".
Read morePolarean Imaging PLC - London-based medical imaging technology company - Receives 510(k) clearance from the US Food & Drug Administration for its specialised magnetic resonance imaging chest coil. The coil may now include Philips 3.0T MRI scanners for the visualisation of the Xenon-129 nuclei.
Read more